Sandoz AG, which specializes in generics and biosimilars, will set up its permanent headquarters in the center of Basel after separating from Novartis in future. According to a press release, Sandoz will move its headquarters from the Novartis campus to the Elsässertor office building in the center of Basel next to the train station after the separation in mid-2024.
CEO of Sandoz Richard Saynor stated in a press release that he is delighted that the company will continue to call Basel its home. He adds: “Our planned location in the heart of the city will allow us to create a working environment that meets our business needs and reflects our identity, culture, and values. Basel is a global center for the life sciences industry, attracting an unrivalled pool of talent and experience that will help us to grow further and achieve our ambition of being the sustainable global leader in generics and biosimilars.”
The move will have no effect on the management of Sandoz’s global business according to the information provided. The new working environment will be designed to enable close collaboration and teamwork across the entire organization.
The pharmaceutical company Novartis announced its intention to separate from Sandoz in August 2022. At Novartis, Sandoz was led as a division for patent-free drugs. The planned separation is expected to take place in the second half of 2023. As an independent company, Sandoz will then list on the SIX Swiss Exchange.